Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir

NCT00708162 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

724

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infection

Interventions

DRUG: Elvitegravir
DRUG: Raltegravir
DRUG: EVG placebo
DRUG: RAL placebo
DRUG: Background regimen

Sponsor

Gilead Sciences